CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE; REPAGLINIDE

All Clinical Trials for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00118950 ↗	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	Completed	Steno Diabetes Center	Phase 4	2001-03-01	Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.
NCT00118950 ↗	Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet	Completed	Steno Diabetes Center Copenhagen	Phase 4	2001-03-01	Background: Metformin is the first drug of choice in obese patients with type-2 diabetes (T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim of this study was to evaluate the effect of metformin versus an insulin-secretagogue, repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in non-obese patients with T2DM. Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96 non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d). followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months with a one month wash-out between interventions.
NCT00118963 ↗	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes	Completed	Steno Diabetes Center	Phase 4	2003-01-01	Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of OHA to be combined with insulin. The aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. Methodology: Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart 30/70, BIAsp30) for a period of 12 months.
NCT00118963 ↗	Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes	Completed	Steno Diabetes Center Copenhagen	Phase 4	2003-01-01	Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference in glycemic control between treatments. Non-obese patients with type-2-diabetes are usually treated with insulin-secretagogues or insulin when diet fails. Since non-obese patients with type-2-diabetes also carry a high risk of cardiovascular events, the use of metformin for this sub-group of patients might be more beneficial. Moreover, when insulin-treatment is initiated ongoing oral hypoglycaemic agents (OHA) are often continued, but in non-obese patients with type-2 diabetes little evidence exist for choosing the optimal class of OHA to be combined with insulin. The aim of the project is therefore to investigate the effect of metformin vs. an insulin-secretagogue (repaglinide) in combination with insulin on glycemic control and non-glycemic cardiovascular risk-factors in non-obese patients with type-2-diabetes, uncontrolled on diet alone. Methodology: Single-center, double-blind, double-dummy, randomized, parallel study involving 100 non-obese (BMI 27 kg/m2 or lower) patients with type-2-diabetes investigating the effect of treatment with metformin vs. repaglinide each in combination with biphasic insulin (Insulin-aspart 30/70, BIAsp30) for a period of 12 months.
NCT00399711 ↗	Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 3	2006-11-01	This trial is conducted in the United States of America (USA). This trial compares the changes in HbA1c after 26 weeks of repaglinide and metformin fixed dose combination tablet given as twice daily versus three times daily regimens or versus twice daily rosiglitazone and metformin fixed dose combination tablet in subjects with type 2 diabetes currently on monotherapy.
NCT00491725 ↗	Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs	Completed	Novo Nordisk A/S	Phase 4	2005-09-01	This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and safety of repaglinide and metformin combination therapy in Chinese subjects with type 2 diabetes inadequately controlled with OAD (oral anti-diabetic drugs).
NCT00568984 ↗	Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes	Completed	Novo Nordisk A/S	Phase 4	2002-11-21	This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of blood glucose control with combination therapy of repaglinide and metformin compared to conventional treatment with a sulphonylurea or metformin in monotherapy in type 2 diabetes

Clinical Trial Conditions for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Condition Name

Condition Name for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Intervention	Trials
Diabetes Mellitus, Type 2	16
Diabetes	11
Type 2 Diabetes	3
Covid19	1

Condition MeSH

Condition MeSH for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Intervention	Trials
Diabetes Mellitus, Type 2	19
Diabetes Mellitus	16
Renal Insufficiency, Chronic	1
Kidney Diseases	1

Clinical Trial Locations for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Trials by Country

Trials by Country for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Location	Trials
United States	41
China	14
Denmark	2
United Kingdom	2
Belgium	2

Trials by US State

Trials by US State for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Location	Trials
Florida	3
Texas	2
New York	2
Georgia	2
Connecticut	1

Clinical Trial Progress for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Clinical Trial Phase

Clinical Trial Phase for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Clinical Trial Phase	Trials
Completed	18
Recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for METFORMIN HYDROCHLORIDE; REPAGLINIDE

Sponsor Name

Sponsor Name for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Sponsor	Trials
Novo Nordisk A/S	12
Steno Diabetes Center	2
Steno Diabetes Center Copenhagen	2

Sponsor Type

Sponsor Type for METFORMIN HYDROCHLORIDE; REPAGLINIDE
Sponsor	Trials
Industry	16
Other	15

Clinical Trials Update, Market Analysis, and Projections for Metformin Hydrochloride and Repaglinide

Last updated: January 27, 2026

Summary

This report provides a detailed overview of the current clinical trial landscape, market dynamics, and future projections for Metformin Hydrochloride and Repaglinide, two prominent oral antidiabetic drugs. Clinicians and industry stakeholders can leverage this analysis to inform strategic decisions, considering ongoing drug innovations, regulatory environments, and market trends through 2028. The data references recent clinical trial activities, sales figures, patent statuses, and regulatory updates.

---

Clinical Trial Landscape for Metformin Hydrochloride and Repaglinide

Current Clinical Trials Overview

Category	Metformin Hydrochloride	Repaglinide
Total Active Trials (as of Q1 2023)	150 (Phases I-IV, ClinicalTrials.gov)	85 (Phases I-IV, ClinicalTrials.gov)
Latest Registered Trial	Dexamethasone + metformin for COVID-19 (NCT04802400, 2022)	Comparative efficacy in elderly patients (NCT04227433, 2021)
Major Trial Focus	Diabetes management, PCOS, NAFLD, COVID-19 complications	Islet cell function, postprandial hyperglycemia, elderly use
Emerging Areas	Combination therapies, drug repurposing, biomarker analysis	Pharmacokinetics, combination therapy, repurposing

Clinical Trial Trends & Insights

• Expansion in Combination Therapies: Increasing trials assess Metformin with other agents such as SGLT2 inhibitors or GLP-1 receptor agonists to enhance glycemic control and cardiovascular outcomes.
• COVID-19 Relevance: Multiple trials are evaluating Metformin's anti-inflammatory and immunomodulatory potential, especially in hospitalized COVID-19 patients.
• Age & Comorbidity Focus: Repaglinide trials increasingly target elderly populations with multiple comorbidities to optimize postprandial glucose regulation.
• Biomarker & Personalized Medicine: Trials evaluating genetic factors influencing drug response are emerging, hinting at tailored treatment approaches.

Regulatory & Patent Updates

Regulatory Status	Metformin Hydrochloride	Repaglinide
FDA Approval	Approved since 1994; following extensions for combination use	Approved since 2000; newer formulations in pipeline
Patent Expiry (Approximate)	Patent expired in 2017; generics dominate	Patent expired in 2015; generic versions widely available
Recent Regulatory Changes	USFDA guidance on extended-release formulations (2021)	No significant recent regulatory updates

---

Market Analysis

Global Market Size and Revenue

Metric	2022 ($ Billion)	Projection 2028 ($ Billion)	CAGR (%)
Metformin Hydrochloride	4.2	6.5	7.4%
Repaglinide	0.3	0.45	8.1%

Note: The global antidiabetic drug market was valued at approximately $80 billion in 2022, with Metformin constituting around 70% share[^1].

Market Drivers

• Rising Diabetes Prevalence: Global diabetes mellitus (DM) patients are projected to reach 700 million by 2045[^2], fueling demand.
• Generic Market Penetration: Expiry of key patents has led to increased generic availability, driving down prices and increasing accessibility.
• Combination Therapy Adoption: Growing preference for multi-drug regimens requires combination formulations, broadening market reach.
• Regulatory Favorability: Approval of new formulations and combination drugs enhances market expansion.

Market Segmentation

Segment	Metformin Hydrochloride	Repaglinide
Formulation	Immediate-release: 500-1000 mg, Extended-release (ER)	0.5 mg, 1 mg, 2 mg tablets
Application	Monotherapy, combination with insulin or other agents	Adjunct therapy for postprandial hyperglycemia
End Users	Adults with Type 2 Diabetes (T2D)	Adults with T2D, especially elderly

Regional Market Breakdown (2022)

Region	Market Share (%)	Key Trends
North America	35%	High adoption; focus on combination therapy, biosimilars
Europe	25%	Regulatory advantages, aging population
Asia-Pacific	30%	Rapid diabetes prevalence increase, affordability
Rest of World	10%	Increasing access via generics, emerging markets

---

Market Projections and Future Outlook (2023-2028)

Parameter	Metformin Hydrochloride	Repaglinide
Sales Growth Rate (CAGR)	7.4%	8.1%
Key Drivers	Market penetration, ongoing clinical trials, geriatric population	Post-meal glucose management trend, combination formulations
Opportunities	Fixed-dose combinations, biosimilars, reformulations	Enhanced formulations, new indications

Key Opportunities & Challenges

Opportunities	Challenges
Expansion into emerging markets	Market saturation in developed regions
Development of fixed-dose combination (FDC) drugs	Regulatory hurdles and biosimilar scrutiny
Biomarker-guided therapy	Patent litigations and generic competition

---

Comparison: Metformin Hydrochloride vs Repaglinide

Parameter	Metformin Hydrochloride	Repaglinide
Mechanism of Action	Reduces hepatic glucose production, increases insulin sensitivity	Stimulates pancreatic insulin secretion
Onset of Action	1-2 hours	20-30 minutes
Duration	4-8 hours	4 hours
Common Side Effects	Gastrointestinal, lactic acidosis (rare)	Hypoglycemia, weight gain
Therapeutic Class	Biguanide	Meglitinide
Formulations	Immediate-release, extended-release	Tablets (0.5-2 mg)
Regulatory Approval Year	1994 (FDA)	2000 (FDA)

---

Regulatory and Industry Trends

• Post-Patent Market Dynamics: Generics have dominated since patent expiries, accounting for over 90% of sales.
• Guideline Integration: Both drugs are aligned with ADA (American Diabetes Association) standards, with Metformin recommended as first-line therapy.
• Emerging Regulations: Focus on safety monitoring, especially for lactic acidosis risk with Metformin and hypoglycemia with Repaglinide.

---

Key Takeaways

• Ongoing Trials: Significant activity in combination therapies and biomarker-driven personalized treatments for both drugs.
• Market Trends: Steady growth driven by diabetes prevalence, affordable generics, and patient-centric formulations.
• Future Opportunities: Fixed-dose combination drugs, improved formulations, and expanding indications pose growth opportunities.
• Regulatory Environment: Favorable for generics, yet increasing scrutiny on safety and biosimilars necessitate vigilant regulatory compliance.
• Competitive Landscape: Market saturation in developed economies; emerging markets offer growth potential for low-cost formulations.

---

Frequently Asked Questions

1. What are the current regulatory considerations for generic versions of Metformin Hydrochloride?

Regulators prioritize bioequivalence studies to ensure generics match brand efficacy and safety. Post-approval surveillance and compliance with manufacturing standards (GMP) are critical, especially given recent updates on extended-release formulations by the FDA[^3].

2. How does Repaglinide compare with other meglitinides, such as Nateglinide?

Repaglinide exhibits a faster onset and shorter duration of action compared to Nateglinide. Both stimulate insulin secretion but differ in pharmacokinetics; choice depends on patient dosing preferences and glycemic patterns[^4].

3. Which markets are expected to see the highest growth for these drugs?

Emerging markets in Asia-Pacific and Latin America demonstrate high growth potential due to increasing diabetes prevalence and affordability of generics[^2].

4. Are there new formulations or combination drugs under clinical development?

Yes. Multiple trials are exploring fixed-dose combinations like Metformin with SGLT2 inhibitors and GLP-1 receptor agonists. Repaglinide combinations with other oral hypoglycemics are also being studied to improve postprandial control[^5].

5. What are the main safety concerns associated with these medications?

• Metformin: Lactic acidosis, especially in renal impairment.
• Repaglinide: Risk of hypoglycemia, particularly if meals are missed or dosing is inappropriate.

---

References

[^1]: MarketWatch. (2023). Global antidiabetic drug market report.
[^2]: International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th edition.
[^3]: US Food and Drug Administration. (2021). Guidance on Extended-Release Oral Forms.
[^4]: Johnson, L. et al. (2022). Comparative Pharmacokinetics of Meglitinides, Journal of Diabetes Research.
[^5]: ClinicalTrials.gov. (2023). Active studies involving Metformin and Repaglinide.

---

This comprehensive analysis equips industry stakeholders, healthcare providers, and policymakers with crucial insights into the evolving landscape of Metformin Hydrochloride and Repaglinide, facilitating informed decision-making aligned with current clinical and market trends.